Biological Sample Collection Kits Market Share

North America Market Analysis

The biological sample collection kits market in North America is estimated to lead with a 41% share during the forecast period due to strong investments in healthcare infrastructure and ongoing advancements in diagnostic technologies. The U.S. is leading the market as the country conducts a large number of clinical lab tests each year, with expenditure surpassing more than 7 billion.  In August 2021, Sedia Biosciences launched Asante DNA Specimen Collection Kits to support innovative specimen collections with the goal of expansion from outside of the U.S. into its domestic market. 

The biological sample collection kits market is also seeing increased traction in Canada, backed by government efforts to reduce gaps in the accessibility of healthcare services. Investments by the local government in healthcare technology and expansion of reach to rural locations and underserved areas have helped this market grow further. The rising incidence of chronic diseases and the increasing adoption rate for personalized medicine are other significant factors driving market growth in Canada.  

Asia Pacific Market Analysis

Asia Pacific is likely to witness lucrative growth in the biological sample collection kits market. The rising healthcare expenditure and heightened focus on early detection of diseases are fueling demand for high-performance diagnostic solutions. The region also offers huge growth opportunities due to the rising demand for personalized and home-based healthcare solutions.  
The market is also bolstered by the government's efforts to enhance healthcare facilities and encourage preventive care in India. The launch of Azooka Labs' mWRAPR in February 2022 a product designed to serve biobanks and research labs working with biological samples, indicates how dynamic the market is evolving within India. 

Government efforts to enhance healthcare access and quality have played a pivotal role in the market expansion of the biological sample collection kits sector, particularly in China. Growing investments in healthcare infrastructure and technology by the government and private sectors is boosting demand for high-quality diagnostic equipment. The RealStar Zoonotic Orthopoxvirus PCR Kit 1.0 by Altona Diagnostics was launched in China in June 2022, augmenting the company’s market position within this region and signaling potential future growth boosters for the area of interest.

The biological sample collection kits market in Japan is well-established and geared toward innovation and quality. The aging population in the country, as well as the increasing demand for personalized medicine, are key factors boosting growth.